Dr. Samuel is currently the Research Associate in the team, a position he has held since July 2019. He enrolled for his PhD program at the University of Kerala and performed his PhD work as an exchange student at the Molecular Cardiology and Angiogenesis Laboratory at the University of Connecticut Health Center (Connecticut, USA; 2006-2010) after which he successfully defended his thesis and was awarded his PhD degree in Biochemistry in December 2010 by the University of Kerala.
During his PhD work, Dr. Samuel mastered techniques such as rat and mouse LAD occlusion (myocardial infarction model), mouse hind-limb ischemia model, confocal microscopy, and western blotting, among others. He has sound research experience in diabetes, endothelial dysfunction, oxidant stress, endoplasmic reticulum stress, myocardial angiogenesis, and tumor angiogenesis.
Prior to joining Dr. Büsselberg’s team as a visiting scientist (Dec 2017 – Dec 2018) Dr. Samuel worked as a post-doctoral associate with Dr. Chris Triggle and Dr. Hong Ding at WCM-Q (2011-2017). During his post-doctoral fellowship, Dr. Samuel was also a recipient of the Junior Scientist Research Experience Program grant (Feb 2013-Nov 2016) awarded by Qatar National Research Fund.
Dr. Samuel has more than 50 peer-reviewed original and review publications, with several published in high-impact journals such as Circulation, Trends in Microbiology, Diabetes, Cancer Treatment Reviews, and Cancers.
Currently, Dr. Samuel is interested in investigating the molecular link between diabetes and cancer (including breast cancer and colorectal cancer), identifying possible key diagnostic and or prognostic biomarkers for the condition, and investigating the potential anti-cancer properties of anti-diabetic drugs such as metformin.
More details of Dr. Samuel’s research background can be found at:
Research: Funding
Completed:
- JSREP3-016-3–009: The role of endoplasmic reticulum (ER) stress in diabetes associated impaired angiogenesis (2013-2016) – awarded by QNRF
Role: LPI
Active:
- NPRP11S-1214-170101: Anti-diabetic drugs in the treatment of breast cancer - identifying the molecular mechanism(s) and key biomarker(s) (June 2019-July 2023) – awarded by QNRF
Role: Research Associate/Team Member